Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.
Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer – expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.
Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, et al. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025;10:49.
Marin A, Mamun AA, Patel H, Akamatsu H, Ye D, Sudhan DR, et al. Acquired secondary HER2 mutations enhance HER2/MAPK signaling and promote resistance to HER2 kinase inhibition in breast cancer. Cancer Res. 2023;83:3145–58.
Rohrig F, Schulze A. The multifaceted roles of fatty acid synthesis in cancer. Nat Rev Cancer. 2016;16:732–49.
Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer. 2007;7:763–77.
Ferraro GB, Ali A, Luengo A, Kodack DP, Deik A, Abbott KL, et al. Fatty acid synthesis is required for breast cancer brain metastasis. Nat Cancer. 2021;2:414–28.
Gruslova A, McClellan B, Balinda HU, Viswanadhapalli S, Alers V, Sareddy GR, et al. FASN inhibition as a potential treatment for endocrine-resistant breast cancer. Breast Cancer Res Treat. 2021;187:375–86.
Sen U, Coleman C, Sen T. Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis. Trends Cancer. 2023;9:480–9.
Yang X, Zhao Y, Shao Q, Jiang G. Cytochrome b561 serves as a potential prognostic biomarker and target for breast cancer. Int J Gen Med. 2021;14:10447–64.
Zhou X, Shen G, Ren D, Guo X, Han J, Guo Q, et al. Expression and clinical prognostic value of CYB561 in breast cancer. J Cancer Res Clin Oncol. 2022;148:1879–92.
Zhou X, Guo X, Han J, Wang M, Liu Z, Ren D, et al. Cytochrome b561 regulates iron metabolism by activating the Akt/mTOR pathway to promote breast cancer cells proliferation. Exp Cell Res. 2023;431:113760.
Zhao T, Wang C, Zhao N, Qiao G, Hua J, Meng D, et al. CYB561 promotes HER2+ breast cancer proliferation by inhibiting H2AFY degradation. Cell Death Discov. 2024;10:38.
Cui Q, Josephraj S, Gu B, Liu JY, Zhang JT. Targeting fatty acid synthase for cancer drug discovery: Retrospective analyses and outlook. Pharmacol Rev. 2026;78:100105.
Zhang J, Hochwald SN. The role of FAK in tumor metabolism and therapy. Pharmacol Ther. 2014;142:154–63.
Lavoie H, Gagnon J, Therrien M. ERK signalling: a master regulator of cell behaviour, life and fate. Nat Rev Mol Cell Biol. 2020;21:607–32.
Hatzikirou H, Basanta D, Simon M, Schaller K, Deutsch A. Go or grow’: the key to the emergence of invasion in tumour progression? Math Med Biol. 2012;29:49–65.
Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell. 2016;166:21–45.
Kroger C, Afeyan A, Mraz J, Eaton EN, Reinhardt F, Khodor YL, et al. Acquisition of a hybrid E/M state is essential for tumorigenicity of basal breast cancer cells. Proc Natl Acad Sci USA. 2019;116:7353–62.
Wang X, Sato R, Brown MS, Hua X, Goldstein JL. SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis. Cell. 1994;77:53–62.
Samson SC, Khan AM, Mendoza MC. ERK signaling for cell migration and invasion. Front Mol Biosci. 2022;9:998475.
Montserrat N, Mozos A, Llobet D, Dolcet X, Pons C, de Herreros AG, et al. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum Pathol. 2012;43:632–43.
Fuhrman B, Nitzan O, Karry R, Volkova N, Dumler I, Aviram M. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis. 2007;195:e108–16.
Boonsong T, Norton L, Chokkalingam K, Jewell K, Macdonald I, Bennett A, et al. Effect of exercise and insulin on SREBP-1c expression in human skeletal muscle: potential roles for the ERK1/2 and Akt signalling pathways. Biochem Soc Trans. 2007;35:1310–1.
Zhou X, An Z, Lei H, Liao H, Guo X. Role of the human cytochrome b561 family in iron metabolism and tumors (Review). Oncol Lett. 2025;29:111.
Guo Z, Chi R, Peng Y, Sun K, Liu H, Guo F, et al. The role and interactive mechanism of endoplasmic reticulum stress and ferroptosis in musculoskeletal disorders. Biomolecules. 2024;14:1369.
Tan TC, Crawford DH, Jaskowski LA, Subramaniam VN, Clouston AD, Crane DI, et al. Excess iron modulates endoplasmic reticulum stress-associated pathways in a mouse model of alcohol and high-fat diet-induced liver injury. Lab Invest. 2013;93:1295–312.
Zeng H, Qin H, Liao M, Zheng E, Luo X, Xiao A, et al. CD36 promotes de novo lipogenesis in hepatocytes through INSIG2-dependent SREBP1 processing. Mol Metab. 2022;57:101428.
Park MN, Choi J, Ribeiro R, Delfino DV, Ko SG, Kim B. The redox-adhesion-exosome (RAX) hub in cancer: lipid peroxidation-driven EMT plasticity and ferroptosis defense with HNE/MDA signaling and lipidomic perspectives. Antioxidants. 2025;14:1474.
Guo F, Zong S, Zhang X, Ren Z, Shao H, Li J, et al. Ferroptosis and metastasis: molecular checkpoints, microenvironmental dynamics, and therapeutic opportunities. Mol Cancer. 2026;25:45.
Zhu Y, Zhou Z, Du X, Lin X, Liang ZM, Chen S, et al. Cancer cell-derived arginine fuels polyamine biosynthesis in tumor-associated macrophages to promote immune evasion. Cancer Cell. 2025;43:1045–60.
Yang J, Yu X, Xiao M, Xu H, Tan Z, Lei Y, et al. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer. Gut. 2025;74:1859–72.
Yang X, Tao Y, Xu Y, Cai W, Shao Q. SLC35A2 expression drives breast cancer progression via ERK pathway activation. FEBS J. 2024;291:1483–505.
